Christina Esdar, PhD (she/her/hers)

Head Oncogenic Signaling Research
The healthcare business of Merck KGaA
Darmstadt, Hessen, Germany

Presentation(s):

• Paper 46 - ANTI-TUMOR EFFECTS OF THE NOVEL KIT MUTANT INHIBITOR M4205/IDRX-42 IN GASTROINTESTINAL STROMAL TUMOR (GIST) XENOGRAFT MODELS

  Friday, November 18, 2022
  10:54 AM – 11:02 AM